Agreements

Date: 2017-11-08

Type of information: Licensing agreement

Compound: small activating RNA (“saRNA”)

Company: Boehringer Ingelheim (Germany) Mina Therapeutics (UK)

Therapeutic area: Fibrotic diseases - Hepatic diseases - Liver diseases

Type agreement: licensing - development

Action mechanism:

• RNAa (RNA activation)

Disease: NASH (non-alcoholic steatohepatitis), fibrotic diseases

Details:

• • On November 8, 2017, BoehringerIngelheim and MiNA Therapeutics , a pioneer in RNA activation therapeutics, yannounced that they have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA’s small activating RNA (“saRNA”) therapeutics platform.
• The new partnership underscores Boehringer Ingelheim’s commitment to advancing innovative new treatment approaches and furthering its comprehensive clinical offerings in cardiometabolic diseases. It combines MiNA’s leading expertise in the development of saRNAs with Boehringer Ingelheim’s experience in bringing first-in-class breakthrough treatments to patients withcardiometabolic disease.
• saRNAs have been demonstrated to activate transcription of specific genes resulting in upregulation of proteins with therapeutic potential. In the new collaboration, Boehringer Ingelheim and MiNA aim to identify targets to restore metabolic functionality of hepatocytes and prevent fibrotic tissue formation in patients with NASH. It will enable Boehringer Ingelheim to rapidly design, profile and develop novel compounds, potentially also creating opportunities for combination with Boehringer Ingelheim’s other NASH pipeline assets.

Financial terms:

• Under the terms of the agreement, MiNA will receive an upfront payment and committedresearch funding as well as potential research, development and regulatory milestonepayments totalling up to € 307 million. In addition, MiNA is entitled to up to double-digitroyalties on sales of selected products resulting from the partnership. No further financial details have been disclosed.

Latest news:

Is general: Yes